Prosight Management, LP 13F holdings, Q4 2024
Holdings as of December 31, 2024 · filings on SEC EDGAR · latest filing →
Prosight Management, LP disclosed 35 US equity positions worth $357.0m in its Q4 2024 13F filing. The largest position was LKFT at 7.9% of the reported book, followed by ACHC and BBIO. Against the Q3 2024 filing, it opened 7 new positions, added to 13 and reduced 14 among the top 35 holdings.
What did Prosight Management, LP own in Q4 2024? Top 35 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q3 2024 |
|---|---|---|---|---|---|---|---|
| 1 | LKFT GALAPAGOS NV | Healthcare | 7.9% | $28.2m | 1,025,000 | -0% | held |
| 2 | ACHC ACADIA HEALTHCARE COMPANY IN | Healthcare | 7.7% | $27.4m | 692,000 | 12113% | added |
| 3 | BBIO BRIDGEBIO PHARMA INC | Healthcare | 7.6% | $27.3m | 995,000 | -8% | reduced |
| 4 | MGTX MEIRAGTX HLDGS PLC | 7.5% | $26.7m | 4,390,837 | -10% | reduced | |
| 5 | ABCL ABCELLERA BIOLOGICS INC | Healthcare | 6.0% | $21.5m | 7,350,000 | -19% | reduced |
| 6 | ADCT ADC THERAPEUTICS SA | Healthcare | 5.3% | $18.9m | 9,515,000 | -1% | reduced |
| 7 | MIRM MIRUM PHARMACEUTICALS INC | Healthcare | 5.2% | $18.7m | 451,127 | -3% | reduced |
| 8 | ICLR ICON PLC | Healthcare | 5.0% | $17.8m | 85,000 | – | new |
| 9 | ROIV ROIVANT SCIENCES LTD | Healthcare | 5.0% | $17.7m | 1,500,000 | -13% | reduced |
| 10 | JANX JANUX THERAPEUTICS INC | Healthcare | 4.9% | $17.7m | 329,768 | 61% | added |
| 11 | SDGR SCHRODINGER INC | Healthcare | 3.9% | $13.9m | 720,500 | 3% | added |
| 12 | RCKT ROCKET PHARMACEUTICALS INC | Healthcare | 3.8% | $13.7m | 1,088,706 | 583% | added |
| 13 | ZYME ZYMEWORKS INC | Healthcare | 3.4% | $12.0m | 820,000 | -11% | reduced |
| 14 | KURA KURA ONCOLOGY INC | Healthcare | 3.2% | $11.5m | 1,325,000 | 88% | added |
| 15 | AM6 AMICUS THERAPEUTICS INC | 2.4% | $8.7m | 920,000 | – | new | |
| 16 | ZBH ZIMMER BIOMET HOLDINGS INC | Healthcare | 2.4% | $8.5m | 80,000 | -52% | reduced |
| 17 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 2.3% | $8.2m | 620,000 | 12% | added |
| 18 | STTK SHATTUCK LABS INC | Healthcare | 2.3% | $8.0m | 6,638,935 | 17% | added |
| 19 | IMVT IMMUNOVANT INC | Healthcare | 2.1% | $7.6m | 305,523 | -17% | reduced |
| 20 | 2655787D BLUEPRINT MEDICINES CORP | 1.6% | $5.8m | 67,000 | 42% | added | |
| 21 | PROTHENA CORP PLC | 1.6% | $5.8m | 418,122 | -14% | reduced | |
| 22 | CTMX CYTOMX THERAPEUTICS INC | Healthcare | 1.1% | $4.0m | 3,905,000 | 29% | added |
| 23 | HAE HAEMONETICS CORP MASS | Healthcare | 1.0% | $3.6m | 46,700 | -28% | reduced |
| 24 | CNC CENTENE CORP DEL | Healthcare | 0.9% | $3.3m | 55,000 | – | new |
| 25 | SGHT SIGHT SCIENCES INC | 0.9% | $3.3m | 908,847 | 71% | added | |
| 26 | LIVN LIVANOVA PLC | Healthcare | 0.9% | $3.2m | 70,000 | -22% | reduced |
| 27 | CRBP CORBUS PHARMACEUTICALS HLDGS | Healthcare | 0.9% | $3.2m | 270,000 | 108% | added |
| 28 | ERAS ERASCA INC | Healthcare | 0.7% | $2.4m | 947,110 | -52% | reduced |
| 29 | SYRE SPYRE THERAPEUTICS INC | 0.5% | $1.9m | 80,000 | – | new | |
| 30 | CDNA CAREDX INC | Healthcare | 0.5% | $1.7m | 80,000 | – | new |
| 31 | MURAL ONCOLOGY PUB LTD CO | 0.4% | $1.5m | 466,822 | -18% | reduced | |
| 32 | FTRE FORTREA HLDGS INC | Healthcare | 0.3% | $1.0m | 55,100 | – | new |
| 33 | RNTX AILERON THERAPEUTICS INC | 0.3% | $931.5k | 404,979 | 9% | added | |
| 34 | IMNM IMMUNOME INC | Healthcare | 0.2% | $577.1k | 54,342 | 39% | added |
| 35 | OKUR ONKURE THERAPEUTICS INC | 0.2% | $548.3k | 63,754 | – | new |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.